Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
NCT ID: NCT02301208
Last Updated: 2014-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
120 participants
INTERVENTIONAL
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose cisplatin arm
concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
Cisplatin
Cisplatin combine with IMRT
High dose cisplatin arm
concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
Cisplatin
Cisplatin combine with IMRT
Low dose nedaplatin arm
concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
Nedaplatin
Nedaplatin combine with IMRT
High dose nedaplatin arm
concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
Nedaplatin
Nedaplatin combine with IMRT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nedaplatin
Nedaplatin combine with IMRT
Cisplatin
Cisplatin combine with IMRT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* T1-2N1-3M0 or T3-4NxM0
* 18-70 years old
* with MRI examinations
* ECOG ≤ 2
* With written consent
Exclusion Criteria
* Pregnancy
* With other severe diseases (blood,liver ,kidney or heart diseases)
* Could not be staged properly
* Without written consent
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
He Xia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
He Xia
Jiangsu Cancer Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JiangsuCIH
Identifier Type: -
Identifier Source: org_study_id